Leaders from the Mass General Cancer Center will present research discoveries and outcomes from clinical trials in cancer at the 2024 American Association for Cancer Research (AACR) Annual Meeting, held April 5-10, in San Diego.
The MGH LVC, the hospital’s volunteer-led auxiliary group, is dedicated to helping patients who have lost their hair due to cancer or other medical treatments through its Images Oncology Boutique, a shop specializing in prosthetics and wigs.
It’s fitting that the investigators who developed a new CAR T-based treatment for glioblastoma called their treatment platform “CAR-TEAM” cells, as it took a true team effort to bring their concept from the lab to the clinic.
Learn more about the findings and importance of a study led by a research and clinical team from the Mass General Cancer Center who is developing new cell therapy for patients with recurrent glioblastoma.
Targeted therapy and world-class care at Mass General Cancer Center has given Ann Malik a new lease on life and a passion for inspiring others. Read her story.
A collaborative project by Mass General Cancer Center researchers to bring the promise of cell therapy to patients with a deadly form of brain cancer has shown dramatic results among the first patients to receive the novel treatment.
Andrew T. Chan, MD, MPH, Director of Epidemiology for the Mass General Cancer Center, and a gastroenterologist focused on cancer prevention among families at high risk of gastrointestinal cancer is working to find out. Chan is co-leading the global team known as PROSPECT, which received a grant of up to $25m over five years, to study early-onset colorectal cancer from Cancer Grand Challenges after an international competition.
Researchers developed a two-part approach to increasing levels of cell-free DNA in the blood to improve the sensitivity of liquid biopsies.
Michael Dougan, MD, PhD, is a senior author of a new study in Clinical Gastroenterology and Hepatology, Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.
The inaugural class of awardees will receive more than $6 million in funding to accelerate groundbreaking cancer research.
An integral part of one of the world’s most distinguished academic medical centers, Mass General Cancer Center is among the leading cancer care providers in the United States.
